Review article: Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.17980 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Matthew J Townsend und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Duke University Hospital, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Gastrointestinal Diseases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 164 Literaturangaben.
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) are effective oncologic agents which frequently cause immune‐related adverse events (irAEs) which can impact multiple organ systems. Onco‐Gastroenterology is a novel and emerging subspecialty within gastroenterology focused on cancer treatment‐related complications. Gastroenterologists must be prepared to identify and manage diverse immune‐mediated toxicities including enterocolitis, hepatitis, pancreatitis and other ICI‐induced toxicities.
Aim
To provide a narrative review of the epidemiology, diagnostic evaluation and management of checkpoint inhibitor‐induced gastrointestinal and hepatic toxicities.
Methods
We searched Cochrane and PubMed databases for articles published through August 2023.
Results
Gastrointestinal and hepatic irAEs include most commonly enterocolitis and hepatitis, but also pancreatitis, oesophagitis, gastritis, motility disorders (gastroparesis) and other rarer toxicities. Guidelines from the National Comprehensive Cancer Network, American Society of Clinical Oncology and European Society for Medical Oncology, in combination with emerging cohort and clinical trial data, offer strategies for management of ICI toxicities. Evaluation of irAEs severity by formal classification and clinical stability, and a thorough workup for alternative etiologies which may clinically mimic irAEs underlie initial management. Treatments include corticosteroids, biologics and other immunosuppressive agents plus supportive care; decisions on dosing, timing and choice of steroid adjuncts and potential for subsequent checkpoint inhibitor dosing are nuanced and toxicity‐specific.
Conclusions
Expanding clinical trial and cohort data have clarified the epidemiology and clinical characteristics of gastrointestinal, pancreatic and hepatic toxicities of ICIs. Guidelines, though valuable, remain based principally on retrospective cohort data. Quality prospective, controlled studies may refine algorithms for treatment and potential immunotherapy rechallenge.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Duke University Hospital, Durham, North Carolina, USA.
- University of California San Francisco School of Medicine, San Francisco, California, USA.
- Division of Gastroenterology, University of California San Francisco Medical Center, San Francisco, California, USA.
- Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Matthew J Townsend, Shilpa Grover
Zitieren
APA
Townsend, M. J., Benque, I. J., Li, M., & Grover, S. (2024). Review article: Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17980
Vancouver
Townsend MJ, Benque IJ, Li M, Grover S. Review article: Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.17980
BibTeX
@article{Townsend2024,
author = {Townsend, Matthew J and Benque, Isaac J and Li, Michael and Grover, Shilpa},
title = {Review article: Contemporary management of gastrointestinal, pancreatic and hepatic toxicities of immune checkpoint inhibitors},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.17980}
}
EUVIMED